This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Globus Medical (GMED) Up 20.5% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q3.
Globus Medical (GMED) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 58.06% and 9.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive's (NUVA) MaXcess Retractor Study Results Positive
by Zacks Equity Research
NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.
Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio
by Zacks Equity Research
Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.
Walgreens' Pharmacy International Arm Faces Coronavirus Woes
by Zacks Equity Research
Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.
Integra (IART) Preliminary Q3 Results Show Recovery in Sales
by Zacks Equity Research
Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.
Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing
by Zacks Equity Research
The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.
Here's Why You Should Add Globus Medical to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.
LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA
by Urmimala Biswas
According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.
Align Technology Rides on Invisalign Amid Coronavirus Woes
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes
by Zacks Equity Research
There has been a steady recovery in the Base Business of LabCorp (LH).
Thermo Fisher Rides on End Market Growth, Test Revenues
by Zacks Equity Research
Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing
by Zacks Equity Research
The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.
AngioDynamics (ANGO) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
QIAGEN (QGEN) Completes Buyout of NeuMoDx, Expands Portfolio
by Zacks Equity Research
QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.
The Zacks Analyst Blog Highlights: Teradyne, ABB, Brooks Automation and Globus Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Teradyne, ABB, Brooks Automation and Globus Medical
4 Robotics Stocks to Skyrocket on Technological Advancement
by Zacks Equity Research
Robotics stocks offer great opportunities for growth investors and recent adoptions have accelerated the industry's growth rapidly.
QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test
by Zacks Equity Research
QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
Bruker Banks on Strategic Innovation Amid Coronavirus Crisis
by Zacks Equity Research
At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.